Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 77.6% in April

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 489,633 shares, an increase of 77.6% from the April 15th total of 275,689 shares. Currently, 8.6% of the shares of the stock are sold short. Based on an average trading volume of 681,214 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday. Westpark Capital assumed coverage on shares of Aligos Therapeutics in a research note on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Finally, Jefferies Financial Group raised shares of Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Institutional Trading of Aligos Therapeutics

Several hedge funds have recently modified their holdings of ALGS. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics during the first quarter valued at approximately $2,602,000. Marshall Wace LLP bought a new stake in shares of Aligos Therapeutics during the fourth quarter valued at approximately $2,504,000. Bank of America Corp DE grew its stake in shares of Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares during the last quarter. SummitTX Capital L.P. bought a new stake in shares of Aligos Therapeutics during the fourth quarter valued at approximately $1,299,000. Finally, Verition Fund Management LLC bought a new stake in shares of Aligos Therapeutics during the fourth quarter valued at approximately $664,000. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Price Performance

ALGS opened at $5.18 on Wednesday. Aligos Therapeutics has a one year low of $5.12 and a one year high of $13.69. The company’s 50 day simple moving average is $6.96 and its 200-day simple moving average is $7.96. The stock has a market capitalization of $32.06 million, a P/E ratio of -0.60 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, beating the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. The business had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $0.25 million. As a group, analysts anticipate that Aligos Therapeutics will post -7.54 EPS for the current year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.